
Opinion|Videos|November 15, 2024
Unmet Needs for Transplant-Eligible NDMM
Key Takeaways
- Pharmacists can enhance medication adherence and manage side effects, crucial for optimizing multiple myeloma therapy.
- Personalized treatment plans should consider patient-specific factors, including comorbidities and genetic profiles.
Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are remaining unmet needs or challenges you see around optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma that pharmacists can address?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
Recognizing Immunizing Pharmacists in the Community
5
















































































































































































































